33 results
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
in this study.
An exploratory assessment of change in body weight showed that subjects receiving oral VK2735 demonstrated dose dependent reductions in body … . The study also includes an evaluation of the pharmacokinetics of VK0214 in AMN patients, as well as an exploratory assessment of changes in plasma levels
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
or improved at Day 34, six days after the last dose of VK2735 was administered, ranging up to 3.6% relative to placebo. An exploratory assessment … weight assessment. 2) Patients treated with VK2735 were titrated to final doses as indicated: 2.5 mg cohort = 2.5 daily x 4 weeks; 5 mg cohort = 2.5 mg
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
at least one dose of study drug and had a valid baseline and post-baseline body weight assessment. 2) Patients treated with VK2735 were titrated to final … one weight-related comorbid condition. The primary endpoint of the study was the assessment of the percent change in body weight from baseline
8-K
EX-99.1
7fq0sw7fq aeq
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
zadytn
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
8-K
EX-99.1
pgv4x 82q8
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
ip9cuubq80hus1mh0m6
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
PRE 14A
6f3sy mswk
17 Apr 23
Preliminary proxy
5:04pm
8-K
EX-99.1
tun popaxsjr
26 Oct 22
Viking Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:32pm
8-K
EX-99.1
kuwaq ilf2ou
27 Jul 22
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
4:11pm
8-K
EX-99.1
7244mx4nt19touznv
27 Apr 22
Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
4:44pm
8-K
EX-99.1
vo6j gxk85t2huwe
9 Feb 22
Viking Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
4:15pm